It has been demonstrated that BCR signaling is constitutively active in CLL patients, leading to BTK being associated with the development of CLL, making it an important drug target in this type of leukemia very common in the Western world.109, 110. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.